SMURF-Therapeutics

SMURF-Therapeutics is a private biotechnology company based in Providence, Rhode Island, focused on developing therapeutics that modulate SMURF2 and hypoxia biology for cancer, anemia, and other hypoxia-related conditions. The company describes itself as a biotechnology pharmaceutical development company and highlights programs spanning anemia, advanced solid tumors, and breast cancer. Its pipeline appears to be entirely preclinical, with disclosed assets including SMURF-101, SMURF-201, and SMURF-301, the last of which is described as a miR-targeting program for breast cancer. Scientific materials and company resources indicate a core strategy centered on the SMURF2-HIF1α pathway, including both small-molecule modulation of SMURF2 and RNA-based approaches such as miR-6883. The company was founded by Wafik S. El-Deiry and has built a scientific and medical leadership team around oncology and translational drug development.